Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy

Pharmacotherapy

Volumn 30, Issue 1, 2010, Pages 43-51

  Inparajah, Miriam ^a   Wong, Cecile ^b   Sibbald, Cathryn ^b   Boodhan, Sabrina ^b   Atenafu, Eshetu G ^c   Naqvi, Ahmed ^b   Dupuis, L Lee ^b,d  

^a SCARBOROUGH HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aminoglycosides; Cancer; Gentamicin; Neutropenia; Once daily dosing; Pediatrics; Pharmacokinetics

Indexed keywords

CIPROFLOXACIN; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ANALYTICAL PARAMETERS; ARTICLE; CANCER THERAPY; CHILD; DEMOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICAL RECORD REVIEW; PRACTICE GUIDELINE; PREDICTION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX RATIO; STUDENT T TEST; UNIVARIATE ANALYSIS;

ADOLESCENT; AGING; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CREATININE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FEVER; GENTAMICINS; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; TREATMENT OUTCOME;

EID: 75149187020     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.1.43     Document Type: Article

References (32)

1. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
2. Glasmacher A, von Lilienfeld-Toal M, Schulte S, Hahn C, Schmidt-Wolf IG, Prentice A. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 2005;11(suppl 5):17-23.
3. Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005;40:S99-104.
4. Lortholary O, Lefort A, Tod M, Chomat AM, Darras-Joly C, Cordonnier C. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect Dis 2008;8:612-20.
5. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2004;114:e111-18.
6. Shankar SM, Jew RK, Bickert BM, Cavalieri GE, Bell LM, Lange BJ. Pharmacokinetics of single daily dose gentamicin in children with cancer. J Pediatr Hematol Oncol 1999;21:284-8.
7. Tomlinson RJ, Ronghe M, Goodbourne C, et al. Once-daily ceftriaxone and gentamicin for the treatment of febrile neutropenia. Arch Dis Child 1999;80:125-31.
8. Bouffet E, Fuhrmann C, Frappaz D, et al. Once-daily antibiotic regimen in paediatric oncology. Arch Dis Child 1994;70:484-7.
9. Jacobson PA, West NJ, Price J, Hutchinson RJ. Gentamicin and tobramycin pharmacokinetics in pediatric bone marrow transplant patients. Ann Pharmacother 1997;31:1127-31.
10. Postovsky S, Ben Arush MW, Kassis E, Elhasid R, Krivoy N. Pharmacokinetic analysis of gentamicin thrice- and single-daily dosage in pediatric cancer patients. Pediatr Hematol Oncol 1997;14:547-54.
11. Sung L, Dupuis LL, Bliss B, et al. Randomized controlled trial of once- versus thrice-daily tobramycin in febrile neutropenic children undergoing stem cell transplantation. J Natl Cancer Inst 2003;95:1869-77.
12. Charnas R, Luthi AR, Ruch W. Once-daily ceftriaxone plus amikacin vs three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Pediatr Infect Dis J 1997;16:346-53.
13. Dupuis LL, Sung L, Taylor T, et al. Tobramycin pharmacokinetics in children with febrile neutropenia undergoing stem cell transplantation: once-daily versus thrice-daily administration. Pharmacotherapy 2004;24:564-73.
14. Traub SL, Kichen L. Estimating ideal body mass in children. Am J Hosp Pharm 1983;40:107-10.
15. Romano S, Fdez de Gatta MM, Calvo MV, Caballero D, Dominguez-Gil A, Lanao JM. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother 1999;44:235-42.
16. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibros 2007;6:327-33.
17. Hennig S, Norris R, Kirkpatrick CMJ. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis: a population pharmacokinetic study. Br J Clin Pharmacol 2008;65:502-10.
18. Lam W, Tjon J, Seto W, et al. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. J Antimicrob Chemother 2007;59:1135-40.
19. Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008;30:674-81.
20. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002;28:936-42.
21. Ho KK, Bryson SM, Thiessen JJ, Greenberg ML, Einarson TR, Leson CL. The effects of age and chemotherapy on gentamicin pharmacokinetics and dosing in pediatric oncology patients. Pharmacotherapy 1995;15:754-64.
22. Sketris I, Lesar T, Zaske DE, Cipolle RJ. Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol 1981;21:288-93.
23. Koshida R, Nakashima E, Taniguchi N, Tsuji A, Benet LZ, Ichimura F. Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts. Pharm Res 1989;6:486-91.
24. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infectious Dis Clin North Am 2003;17:503-28.
25. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infectious Dis 1987;155:93-9.
26. Rosario MC, Thomson AH, Jodrell DI, Sharp CA, Elliott HL. Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol 1998;46:229-36.
27. Barclay ML, Duffull SB, Begg EJ, Buttimore RC. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Aust N Z J Med 1995;25:230-5.
28. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995;39:605-9.
29. Chan GL. Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity. DICP 1989;23:788-94.
30. Murry KR, McKinnon PS, Mitrzyk B, Rybak MJ. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 1999;19:1252-60.
31. Smyth A, Tan KHV, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis: the TOPIC study, a randomised controlled trial. Lancet 2005;365:573-8.
32. Smyth AR, Tan KH. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2006;(3):CD002009.